Diagnostic Value of a Group of MicroRNA Genes Hypermethylated in Ovarian Carcinoma
- Authors: Braga E.A.1,2, Loginov V.I.1,2, Filippova E.A.1, Burdennyi A.M.1, Pronina I.V.1, Kazubskaya T.P.3, Khodyrev D.S.4, Utkin D.O.3, Kushlinskii D.N.5, Adamyan L.V.5, Kuslinskii N.E.3
- 
							Affiliations: 
							- Research Institute of General Pathology and Pathophysiology
- Research Center of medical Genetics
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation
- Federal Scientific and Clinical Center of Specialized Medical Assistance and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation
- V. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russian Federation
 
- Issue: Vol 166, No 2 (2018)
- Pages: 253-256
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/240938
- DOI: https://doi.org/10.1007/s10517-018-4326-0
- ID: 240938
Cite item
Abstract
The study was designed to determine genes of microRNAs hypermethylated in malignant ovarian tumors and to select new diagnostic and prognostic markers of the disease and effective system of markers. Using methyl-specific PCR and a representative sample of 54 ovarian cancer specimens, we determined 5 microRNA genes (MIR-34b/c, MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) hypermethylated in the majority of tumor samples in comparison with paired samples of histologically unchanged tissue (48-57% vs. 4-19%, p<0.001). Using ROC-analysis, we selected an effective system of 4 markers for diagnosis of ovarian cancer (MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) characterized by high sensitivity and specificity (up to 87-94% at AUC=0.92) relative to the conventional norm (54 paired samples of histologically unchanged tissue) and absolute norm (18 ovarian tissue samples from subjects who died from non-tumor diseases). It was also shown that methylation of MIR-129-2, MIR-9-1, and MIR-34b/c genes is significantly (p<0.01) correlated with the clinical stage or the presence of metastases. The results indicate that epigenetic modifications of the studied microRNA genes are involved in the pathogenesis and progression of ovarian cancer and attest to their diagnostic and prognostic potential.
About the authors
E. A. Braga
Research Institute of General Pathology and Pathophysiology; Research Center of medical Genetics
							Author for correspondence.
							Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow; Moscow						
V. I. Loginov
Research Institute of General Pathology and Pathophysiology; Research Center of medical Genetics
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow; Moscow						
E. A. Filippova
Research Institute of General Pathology and Pathophysiology
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow						
A. M. Burdennyi
Research Institute of General Pathology and Pathophysiology
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow						
I. V. Pronina
Research Institute of General Pathology and Pathophysiology
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow						
T. P. Kazubskaya
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow						
D. S. Khodyrev
Federal Scientific and Clinical Center of Specialized Medical Assistance and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow						
D. O. Utkin
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow						
D. N. Kushlinskii
V. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russian Federation
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow						
L. V. Adamyan
V. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russian Federation
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow						
N. E. Kuslinskii
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation
														Email: eleonora10_45@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					